JP6688748B2 - 片頭痛の治療または改善方法 - Google Patents

片頭痛の治療または改善方法 Download PDF

Info

Publication number
JP6688748B2
JP6688748B2 JP2016575106A JP2016575106A JP6688748B2 JP 6688748 B2 JP6688748 B2 JP 6688748B2 JP 2016575106 A JP2016575106 A JP 2016575106A JP 2016575106 A JP2016575106 A JP 2016575106A JP 6688748 B2 JP6688748 B2 JP 6688748B2
Authority
JP
Japan
Prior art keywords
migraine
glyx
patient
aura
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016575106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519778A (ja
JP2017519778A5 (enExample
Inventor
ジョーゼフ アール モスカル
ジョーゼフ アール モスカル
パトリック スタントン
パトリック スタントン
Original Assignee
ノースウェスタン ユニバーシティ
ノースウェスタン ユニバーシティ
ノーレックス インコーポレイテッド
ノーレックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウェスタン ユニバーシティ, ノースウェスタン ユニバーシティ, ノーレックス インコーポレイテッド, ノーレックス インコーポレイテッド filed Critical ノースウェスタン ユニバーシティ
Publication of JP2017519778A publication Critical patent/JP2017519778A/ja
Publication of JP2017519778A5 publication Critical patent/JP2017519778A5/ja
Application granted granted Critical
Publication of JP6688748B2 publication Critical patent/JP6688748B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016575106A 2014-06-23 2015-06-23 片頭痛の治療または改善方法 Active JP6688748B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462015727P 2014-06-23 2014-06-23
US62/015,727 2014-06-23
US201562109386P 2015-01-29 2015-01-29
US62/109,386 2015-01-29
PCT/US2015/037177 WO2015200322A1 (en) 2014-06-23 2015-06-23 Methods of treating or ameliorating migraine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020068289A Division JP2020114863A (ja) 2014-06-23 2020-04-06 片頭痛の治療または改善方法

Publications (3)

Publication Number Publication Date
JP2017519778A JP2017519778A (ja) 2017-07-20
JP2017519778A5 JP2017519778A5 (enExample) 2018-08-02
JP6688748B2 true JP6688748B2 (ja) 2020-04-28

Family

ID=54938737

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016575106A Active JP6688748B2 (ja) 2014-06-23 2015-06-23 片頭痛の治療または改善方法
JP2020068289A Pending JP2020114863A (ja) 2014-06-23 2020-04-06 片頭痛の治療または改善方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020068289A Pending JP2020114863A (ja) 2014-06-23 2020-04-06 片頭痛の治療または改善方法

Country Status (10)

Country Link
EP (1) EP3157943A4 (enExample)
JP (2) JP6688748B2 (enExample)
KR (1) KR20170018072A (enExample)
CN (1) CN106661085A (enExample)
AU (1) AU2015280108B2 (enExample)
BR (1) BR112016030375A8 (enExample)
CA (1) CA2953170A1 (enExample)
MX (1) MX2016017388A (enExample)
RU (1) RU2721401C2 (enExample)
WO (1) WO2015200322A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210151836A (ko) * 2019-04-15 2021-12-14 페린 파마슈티칼즈, 인코포레이티드 편두통의 치료

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006468A1 (en) * 1993-09-01 1995-03-09 Smithkline Beecham Corporation Method for treating migraine headaches
US6884910B2 (en) * 2000-08-25 2005-04-26 Research Corporation Technologies, Inc. Uses for amino acid anticonvulsants
US20040053835A1 (en) * 2000-11-17 2004-03-18 Sophia Kossida Regulation of human nmda receptor
ZA200506715B (en) * 2003-03-06 2007-05-30 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
AU2009274876C1 (en) * 2008-07-23 2016-08-18 Kyowa Kirin Co., Ltd. Therapeutic agent for migraine
WO2011003064A2 (en) * 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
PT2485751E (pt) * 2009-10-05 2014-09-01 Univ Northwestern Glyx-13 para uso num método para tratar depressão refratária
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG10201501050RA (en) * 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
US20140107037A1 (en) * 2011-04-27 2014-04-17 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
AU2013329000A1 (en) * 2012-10-12 2015-04-30 Northwestern University Methods of identifying compounds for treating depression and other related diseases

Also Published As

Publication number Publication date
JP2020114863A (ja) 2020-07-30
CN106661085A (zh) 2017-05-10
AU2015280108B2 (en) 2019-11-28
MX2016017388A (es) 2018-02-19
EP3157943A1 (en) 2017-04-26
RU2017101410A3 (enExample) 2019-01-21
BR112016030375A2 (pt) 2017-08-15
JP2017519778A (ja) 2017-07-20
RU2721401C2 (ru) 2020-05-19
AU2015280108A1 (en) 2017-01-19
CA2953170A1 (en) 2015-12-30
BR112016030375A8 (pt) 2021-07-13
WO2015200322A1 (en) 2015-12-30
RU2017101410A (ru) 2018-07-24
KR20170018072A (ko) 2017-02-15
EP3157943A4 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
ES2750728T3 (es) Uso de cannabinoides en combinación con Aripriprazol
ES2791764T3 (es) Composiciones de buprenorfina y antagonistas del receptor de opioides mu
RU2499598C2 (ru) Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
US10238622B2 (en) Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE)
Yin et al. Paeoniflorin exerts analgesic and hypnotic effects via adenosine A1 receptors in a mouse neuropathic pain model
JP4152186B2 (ja) 減少された神経ステロイド活性に関連する疾患の治療でのｇａｂａエンハンサー
US20090163451A1 (en) Methods for treating visceral pain
ES2385138T3 (es) Modelo de roedor de enfermedad para dolor muscular crónico
US11419857B2 (en) Methods and compositions for treating pain
EP3258930A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
JP6688748B2 (ja) 片頭痛の治療または改善方法
US20200129528A1 (en) Methods for treating blood pressure conditions using aminosterol compositions
RU2005133478A (ru) Применение производных карбамазепина для лечения возбуждения у пациентов, страдающих деменцией
Yoshizumi et al. Central mechanisms of apomorphine and m-chlorophenylpiperazine on synergistic action for ejaculation in rats
Saad et al. Nitric oxide of the supraoptic nucleus influences the salivary secretion, sodium renal excretion, urinary volume and arterial blood pressure induced by pilocarpine
JP2012102069A (ja) 早漏治療剤
Holland The orexins and their involvement in the modulation of trigeminovascular nociceptive transmission
Goodfellow Altered NMDA Receptor Composition and Function Contribute to Deficits in Forebrain-Dependent Learning and Memory in Adult Rats Exposed to Ethanol as Neonates
Woodall Actions of two intravenous anaesthetic agents, propofol and ketamine
Chang Dopamine D3 regulation of sensorimotor gating
Ádám et al. Second Joint Meeting of the LXXIV Annual Meeting of the Hungarian Physiological Society and the Hungarian Society for Experimental and Clinical Pharmacology
Chandler The role of GABAB receptors in temporal lobe epilepsy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200406

R150 Certificate of patent or registration of utility model

Ref document number: 6688748

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250